Efficacy of antimicrobials in preventing resistance in solid organ transplant recipients: A systematic review of clinical trials

Table 2 Summary of the main characteristics of the studies

Ref.	Patients	Intervention/control	Microorganisms studied	Incidence of antimicrobial resistance	Adverse events
Rock et al[12]	1085	Routine and discharge patient room cleaning using ultraviolet-C light vs routine and discharge patient room cleaning	Vancomycin-resistant enterococci and Clostridioides difficile	6.52 vs 6.68 per 1000 patient-days in vancomycin-resistant enterococci (P > 0.05) and 3.78 vs 2.64 per 1000 patient-days in Clostridioides difficile infections (P > 0.05)	Not reported
Avery et al[13]	352	Maribavir 400 mg twice daily versus valganciclovir/ganciclovir, foscarnet, or cidofovir	Cytomegalovirus	44.4% vs 76.1% (P < 0.05)	40 deaths, dysgeusia, nausea, diarrhea
Fariñas et al[14]	105	Colistin-neomycin vs no treatment	Multidrug-resistant (Enterobacterales)	9.4% vs 13.5% (P > 0.05)	Diarrhea
Papanicolaou et al[15]	120	Maribavir 400, 800, or 1200 mg at a ratio of 1:1:1	Cytomegalovirus	30%, 37.5%, 27.5% (P > 0.05)	32 deaths, dysgeusia, nausea
Boivin et al[16]	275	Ganciclovir vs valganciclovir	Cytomegalovirus	2.3% vs 3.6% (P > 0.05)	2 deaths, gastrointestinal problem
Boivin et al[17]	80	Valganciclovir vs ganciclovir	Cytomegalovirus	2.5% vs 2.5% (P > 0.05)	1 death, 23 grafts rejected, abdominal pain, diarrhea
Boivin et al[18]	301	Valganciclovir vs ganciclovir	Cytomegalovirus	0% vs 6.1% (P < 0.05)	1 graft rejected